Enovis (ENOV) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.90
- Estimate
- $0.85
- Surprise
- +6.3%
- Revenue (period 2026-07-03)
- $582.8M
- Score at report (before → after)
- 6.2 → 6.2/10
Revenue source: xbrl.
How the report landed
Enovis (ENOV) beat the $0.85 estimate with adjusted EPS of $0.90 — a clear 6.3% upside surprise. TrendMatrix's engine moved from Hold (6.2/10) to Buy (Wait) at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ENOV Hold at 6.1/10.
4 of the last 4 quarters beat the estimate; this quarter's +6.3% surprise compares with a +11.2% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Strong earnings beat streak (4/4)
- Attractive valuation
What argues against it
- Elevated risk factors
- Below 200-MA, MA slope -5.8%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.57
- Price target
- $31.39
- Stop
- $17.27
- Upside to target
- +69.0%
- Reward-to-risk
- 6.9:1
Model outputs from TrendMatrix’s engine as of 2026-10-15 — shown for context, not personalized investment advice.
ENOV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.10B
- P/E (fwd)
- 5.4
- 52-week range
- $16.70–$34.28
- Off 52-week high
- 45.8%
- RSI (14)
- 53
- Volume vs avg
- 0.72×
- Score today
- 6.1/10